ClinicalTrials.gg
Drug

Asciminib clinical trials

Also written ABL001.

studies test it
35
open now
18
in phase 3
6
first study started
2014

How each study uses asciminib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the asciminib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Oct 2021 · SCEMBLIX · NDA 215358 (FDA, Drugs@FDA)
European Union
25 Aug 2022 · Scemblix · EMEA/H/C/005605 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Asciminib
22
Asciminib single agent
2

Brand

Scemblix
1

Development codes

ABL001
24

Studies by the year they started

33 studies that test it; most in 2021 (6); 2 more planned to start later

Studies that test asciminib, by start year
YearStudies
20141
20161
20171
20183
20191
20201
20216
20224
20231
20244
20254
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
12
Phase 2
18
Phase 3
6
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 19

Novartis Pharmaceuticals (16) · M.D. Anderson Cancer Center (5) · City of Hope Medical Center (2) · University of Jena (1) · University of Alabama at Birmingham (1) · Washington University School of Medicine (1) · Sunil G. Iyer (1) · Thomas Ernst, Prof. Dr. med. (1)

Often tested with

Tested in the same studies.

Imatinib (2) · Nilotinib (2) · Dasatinib (2) · Fludarabine (1) · Cytarabine (1) · Idarubicin (1) · Venetoclax (1) · Inotuzumab Ozogamicin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test asciminib.

Studies

Open first, then newest update. How each study uses asciminib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 35

See all 35 studies that test asciminib →

Given beside what is tested · 2 — asciminib is usual care or a partner of the new treatment

Codes

What other systems call asciminib · ClinicalTrials.gg INT000758

  • MeSH (NLM) C000621806asciminibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) L1F3R18W77ASCIMINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2584304One source FDA
  • Wikidata Q27074535asciminibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C114494AsciminibOne source FDA
  • DrugBank DB12597One source Wikidata

Also registered as asciminib hydrochloride (UNII C5U34S9XFV · RxNorm 2584303).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.